Please login to the form below

Not currently logged in
Email:
Password:

Bridion

This page shows the latest Bridion news and features for those working in and with pharma, biotech and healthcare.

FDA approvals hit 19-year high

FDA approvals hit 19-year high

Among these, the FDA highlighting Merck &Co's neuromuscular blockade reversal agent Bridion (sugammadex), Pfizer's CD4/6 inhibitor Ibrance (palbociclib) for breast cancer and Boehringer Ingelheim's Praxbind (idarucizumab), a

Latest news

  • Merck finally bags FDA approval for Bridion Merck finally bags FDA approval for Bridion

    Merck finally bags FDA approval for Bridion. Follows three unsuccessful attempts to gain a US licence for the drug. ... Merck said it plans to launch Bridion in January and will announce Bridion's price at that time.

  • At long last, Merck gets FDA panel backing for Bridion At long last, Merck gets FDA panel backing for Bridion

    After several knockbacks, Merck &Co has finally moved a key step closer to securing FDA approval for its muscle relaxant reversal agent Bridion. ... Bridion (sugammadex) was first rejected by the FDA in 2008, and was turned down once again in 2013.

  • Merck faces another Bridion knockback Merck faces another Bridion knockback

    Merck faces another Bridion knockback. It is seven years since the FDA initially rejected it. ... Bridion was acquired by Merck when it took over Schering-Plough in 2009.

  • R&D in the firing line as Merck & Co axes 8,500 jobs R&D in the firing line as Merck & Co axes 8,500 jobs

    Recent setbacks in Merck's late-stage pipeline include a delay in US approval of anaesthesia drug Bridion (sugammadex) and an FDA rejection for insomnia candidate suvorexant, while the company has

  • FDA rejects Merck muscle relaxant drug once again FDA rejects Merck muscle relaxant drug once again

    FDA rejects Merck muscle relaxant drug once again. Regulator still has hypersensitivity concerns about Bridion. ... reactions that was requested by the FDA when it turned Bridion down for the first time in 2008.

More from news
Approximately 6 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics